Global Anxiety and Panic Disorders Drugs Market - Analysis, Technologies & Forecasts to 2021 - Key Vendors are AstraZeneca, Eli Lilly, GlaxoSmithKline & Pfizer - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Anxiety and Panic Disorders Drugs Market 2017-2021" report to their offering.

The global anxiety and panic disorders drugs market to grow at a CAGR of 1.78 % during the period 2017-2021.

The report, Global Anxiety and Panic Disorders Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers for this market is increasing stress in day-to-day life. We are living in an era where modernization and the demands of modern lifestyle come with its sets of limitations. The modern lifestyle is full of challenges of coping up with professional and family life leading to stressful situations, which occurs more often. Not only the demands of our modern culture but heavier workloads, fear of being unemployed, deadlines for completing the task, night shifts, and personal issues are some of the factors that account for burdening one's life. These challenges faced by an individual for a long time coupled with unhealthy lifestyles gives rise to many mental disorders such as anxiety and panic disorders.

Key vendors

  • AstraZeneca
  • Eli Lilly
  • GlaxoSmithKline
  • Pfizer

Other prominent vendors

  • Azevan Pharmaceuticals
  • Baxter
  • Bristol-Myers Squibb
  • F. Hoffman-La Roche

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Disease overview

PART 06: Pipeline analysis

PART 07: Market landscape

PART 08: Market segmentation by drug class

PART 09: Geographical segmentation

PART 10: Decision framework

PART 11: Drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

PART 14: Key vendor analysis

PART 15: Appendix

For more information about this report visit http://www.researchandmarkets.com/research/xm7tjj/global_anxiety

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Mental Health , Mental Disorders Drugs , Anxiety Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Mental Health , Mental Disorders Drugs , Anxiety Drugs